Talantov Dmitri, Mazumder Abhijit, Yu Jack X, Briggs Thomas, Jiang Yuqiu, Backus John, Atkins David, Wang Yixin
Veridex, LLC, a Johnson & Johnson Company, San Diego, California 92121, USA.
Clin Cancer Res. 2005 Oct 15;11(20):7234-42. doi: 10.1158/1078-0432.CCR-05-0683.
Cutaneous melanoma is a common, aggressive cancer with increasing incidence. The identification of melanoma-specific deregulated genes could provide molecular markers for lymph node staging assays and further insight into melanoma tumorigenesis.
Total RNA isolated from 45 primary melanoma, 18 benign skin nevi, and 7 normal skin tissue specimens were analyzed on an Affymetrix Hu133A microarray containing 22,000 probe sets.
Hierarchical clustering revealed a distinct separation of the melanoma samples from the benign and normal specimens. Novel genes associated with malignant melanoma were identified. Differential gene expression of two melanoma-specific genes, PLAB and L1CAM, were tested by a one-step quantitative reverse transcription-PCR assay on primary malignant melanoma, benign nevi, and normal skin samples, as well as on malignant melanoma lymph node metastasis and melanoma-free lymph nodes. The performance of the markers was compared with conventional melanoma markers such as tyrosinase, gp100, and MART1.
Our study systematically identified novel melanoma-specific genes and showed the feasibility of using a combination of PLAB and L1CAM in a reverse transcription-PCR assay to differentiate clinically relevant samples containing benign or malignant melanocytes.
皮肤黑色素瘤是一种常见的侵袭性癌症，发病率不断上升。鉴定黑色素瘤特异性失调基因可为淋巴结分期检测提供分子标志物，并进一步深入了解黑色素瘤的肿瘤发生机制。
从45例原发性黑色素瘤、18例良性皮肤痣和7例正常皮肤组织标本中分离出的总RNA，在包含22,000个探针组的Affymetrix Hu133A微阵列上进行分析。
层次聚类显示黑色素瘤样本与良性和正常标本明显分离。鉴定出了与恶性黑色素瘤相关的新基因。通过一步定量逆转录PCR检测，对原发性恶性黑色素瘤、良性痣、正常皮肤样本以及恶性黑色素瘤淋巴结转移灶和无黑色素瘤的淋巴结，检测了两个黑色素瘤特异性基因PLAB和L1CAM的差异基因表达。将这些标志物的性能与传统的黑色素瘤标志物如酪氨酸酶、gp100和MART1进行了比较。
我们的研究系统地鉴定了新的黑色素瘤特异性基因，并表明在逆转录PCR检测中使用PLAB和L1CAM组合来区分含有良性或恶性黑素细胞的临床相关样本是可行的。
